首页 > 市场调查报告书 > 製药

药物开发临床实验开发业务受託机关

临床前CRO市场规模、份额和成长分析（按服务、模式、应用、最终用户和地区划分）－2026-2033年产业预测

市场调查报告书

商品编码

1903209

临床前CRO市场规模、份额和成长分析（按服务、模式、应用、最终用户和地区划分）－2026-2033年产业预测

Preclinical CRO Market Size, Share, and Growth Analysis, By Service (Bioanalysis and DMPK studies, Toxicology Testing), By Model, By Application, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月24日 | 出版商:

SkyQuest | 英文 175 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球非临床 CRO 市场规模预计在 2024 年达到 70.1 亿美元，从 2025 年的 76.9 亿美元成长到 2033 年的 160.1 亿美元，在预测期（2026-2033 年）内复合年增长率为 9.6%。

全球临床前CRO（受託研究机构）市场正经历显着成长，这主要得益于生物製药公司、医疗设备製造商和政府机构对CRO服务需求的不断增长。慢性病和遗传性疾病发生率的上升促使这些机构加强对创新药物和诊断设备的研发投入。将临床前研究外包给CRO，使企业能够专注于自身核心竞争力，同时获得专业支援以提升研发能力。此外，开发救命药物的紧迫性使得临床前CRO在药物开发和商业化策略中扮演着至关重要的角色，这提升了它们在不断发展的生物製药行业中的重要性，并推动了市场扩张。

全球临床前CRO市场驱动因素

临床前CRO服务的扩张主要受生物製药产业的快速发展所驱动。随着生物製药公司不断拓展创新治疗方法的研发领域，它们越来越多地将关键的临床前研究（包括疗效和毒性评估）外包给CRO。随着企业在加速复杂药物研发的同时优化资源和专业知识，这种外包趋势预计将在未来推动对临床前CRO服务的需求。因此，对CRO日益增长的依赖预计将推动临床前市场领域的成长。

限制全球临床前CRO市场的因素

全球临床前CRO市场的主要限制因素之一源自于临床前研究外包带来的挑战。生物製药公司在使用第三方CRO时，会放弃对研发过程的部分监管权。这种控制权的丧失会导致延误、沟通不良和结果不一致，从而阻碍研发进度。因此，这种依赖性会阻碍高效率的研发，并影响药物研发的整体品质和进度。与第三方机构保持有效的协作和沟通至关重要，但却难以实现，最终会影响该领域的创新和进步。

全球临床前CRO市场趋势

全球临床前CRO市场正经历自动化和人工智慧（AI）融合的显着趋势，这从根本上重塑了其营运方式。这种变革提高了研究效率和准确性，从而缩短了研发週期并显着降低了成本。人工智慧驱动的解决方案正在优化数据处理、预测建模和药物开发，使企业能够在保持高品质标准的同时更快地交付成果。随着这些技术的应用日益广泛，临床前CRO产业预计将持续转型。相关人员将越来越依赖先进的分析技术和自动化来简化工作流程，并在整个药物开发过程中提高生产力。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Charles River Laboratories International, Inc.（USA）
Labcorp Drug Development（USA）
Eurofins Scientific（Luxembourg）
ICON plc（Ireland）
IQVIA（USA）
Parexel International Corporation（USA）
PPD（USA）
Syneos Health（USA）
Crown Bioscience（USA）
Envigo（USA）
Intertek Group plc（UK）
SGS SA（Switzerland）
MPI Research（USA）
Worldwide Clinical Trials（USA）
Inotiv, Inc.（USA）
Jubilant Biosys Ltd.（India）

结论与建议

简介目录

Product Code: SQMIG35D2298

Global Preclinical CRO Market size was valued at USD 7.01 Billion in 2024 and is poised to grow from USD 7.69 Billion in 2025 to USD 16.01 Billion by 2033, growing at a CAGR of 9.6% during the forecast period (2026-2033).

The global preclinical Contract Research Organization (CRO) market is experiencing significant growth, driven by the increasing demand from biopharmaceutical companies, medical device firms, and government agencies that utilize CRO services. The rising incidence of chronic illnesses and genetic disorders has prompted these organizations to invest extensively in research for innovative drugs and diagnostic devices. By outsourcing preclinical research to CROs, companies can concentrate on their primary activities while receiving specialized support that enhances their research and development capabilities. Furthermore, the urgent need for the creation of life-saving medications positions preclinical CROs as vital players in drug development and commercialization strategies, reinforcing their importance in the evolving biopharmaceutical landscape and propelling market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preclinical CRO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preclinical CRO Market Segments Analysis

Global Preclinical CRO Market is segmented by Service, Model, Application, End User and region. Based on Service, the market is segmented into Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology and Others. Based on Model, the market is segmented into Patient-Derived Organoid (PDO) Model and Patient-Derived Xenograft Model. Based on Application, the market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Metabolic Disorders and Others. Based on End User, the market is segmented into Pharmaceutical and Biotechnological Companies, Government and Academic Institutes, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Preclinical CRO Market

A significant catalyst for the expansion of preclinical Contract Research Organization (CRO) services is the swift advancement of the biopharmaceutical industry. As biopharmaceutical companies increasingly venture into the development of innovative therapies, they are turning to CROs for essential preclinical testing, including drug efficacy and toxicity assessments. This tendency towards outsourcing is expected to drive future demand for preclinical CRO services, as firms seek to optimize their resources and expertise while navigating the complexities of drug development. Consequently, the reliance on CROs is anticipated to bolster growth within the preclinical segment of the market.

Restraints in the Global Preclinical CRO Market

One significant constraint in the Global Preclinical CRO market stems from the challenges associated with outsourcing preclinical testing. When biopharmaceutical companies engage third-party CROs, they may relinquish some degree of oversight over the development processes. This loss of control can hinder progress, as it often results in delays, miscommunication, and inconsistent outcomes. Consequently, such dependencies create obstacles to efficient research and may impact the overall quality and timelines of drug development. The ability to maintain effective collaboration and communication with third-party entities is critical, yet can be difficult to achieve, ultimately affecting innovation and advancement in the field.

Market Trends of the Global Preclinical CRO Market

The Global Preclinical CRO market is witnessing a significant trend towards the integration of automation and artificial intelligence (AI), fundamentally reshaping operational methodologies. This evolution enhances research efficiency and accuracy, leading to expedited timelines and substantial cost savings. AI-driven solutions are optimizing data processing, predictive modeling, and drug development, enabling companies to deliver results more quickly while maintaining high-quality standards. As these technologies are increasingly adopted, the preclinical CRO sector is expected to experience a continuous transformation, with stakeholders increasingly relying on advanced analytics and automation to streamline workflows and improve overall productivity in the drug development journey.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Preclinical CRO Market Size by Service & CAGR (2026-2033)

Market Overview
Bioanalysis and DMPK studies
- In vitro ADME
- In-vivo PK
Toxicology Testing
- GLP
- Non-GLP
Compound Management
- Process R&D
- Custom Synthesis
- Others
Chemistry
- Medicinal Chemistry
- Computation Chemistry
Safety Pharmacology
Others

Global Preclinical CRO Market Size by Model & CAGR (2026-2033)

Market Overview
Patient-Derived Organoid (PDO) Model
Patient-Derived Xenograft Model

Global Preclinical CRO Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Neurology
Cardiology
Infectious Diseases
Metabolic Disorders
Others

Global Preclinical CRO Market Size by End User & CAGR (2026-2033)

Market Overview
Pharmaceutical and Biotechnological Companies
Government and Academic Institutes
Medical Device Companies
Others

Global Preclinical CRO Market Size & CAGR (2026-2033)

North America (Service, Model, Application, End User)
- US
- Canada
Europe (Service, Model, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service, Model, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service, Model, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service, Model, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Charles River Laboratories International, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Labcorp Drug Development (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eurofins Scientific (Luxembourg)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ICON plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IQVIA (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Parexel International Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PPD (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Syneos Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Crown Bioscience (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Envigo (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intertek Group plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SGS SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MPI Research (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Worldwide Clinical Trials (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inotiv, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jubilant Biosys Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments